Home » Stocks » OPT

Opthea Limited (OPT)

Stock Price: $11.93 USD 0.18 (1.53%)
Updated Jan 25, 2021 1:56 PM EST - Market open
Market Cap 507.33M
Revenue (ttm) 61,405
Net Income (ttm) -11.62M
Shares Out 43.14M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE 6.73
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $11.93
Previous Close $11.75
Change ($) 0.18
Change (%) 1.53%
Day's Open 11.87
Day's Range 11.91 - 12.35
Day's Volume 1,411
52-Week Range 11.11 - 13.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 3 months ago

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

Other stocks mentioned: ALGS, ARRY, CDAK, EBC, PRAX, SPEL, TARS
GlobeNewsWire - 3 months ago

MELBOURNE, Australia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent a...

Benzinga - 3 months ago

Opthea, an Australian clinical stage biotech company, is going public to help fund its Phase 3 trials and take on two large biotech companies. About Opthea: The main area of focus for Opthea L...

Seeking Alpha - 3 months ago

Opthea has filed proposed terms to raise capital from a U.S. IPO.

About OPT

Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The c... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2020
CEO
Megan Baldwin
Employees
8
Stock Exchange
NASDAQ
Ticker Symbol
OPT
Full Company Profile

Financial Performance

In 2020, Opthea's revenue was 87,075, a decrease of -45.26% compared to the previous year's 159,064. Losses were -16.53 million, -20.95% less than in 2019.

Financial numbers in millions AUD.
Financial Statements